MASS trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MASS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, 908 Devices Inc. (MASS) has a Wall Street consensus price target of N/A, based on estimates from 5 covering analysts. The company has a market capitalization of $327M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MASS trades at a trailing P/E of 16.0x. Analysts expect EPS to grow +70.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MASIMasimo Corporation | $9.4B | $179.95 | $180.00 | +0.0% | Buy | 32.7x | 23 |
WATWaters Corporation | $23.4B | $358.25 | $395.25 | +11.2% | Hold | 24.5x | 35 |
AAgilent Technologies, Inc. | $35.7B | $126.49 | $154.75 | +21.8% | Buy | 21.0x | 41 |
TMOThermo Fisher Scientific Inc. | $172.4B | $464.01 | $599.70 | +29.1% | Buy | 18.7x | 42 |
BRKRBruker Corporation | $8.6B | $56.53 | $47.67 | -16.7% | Buy | 27.0x | 32 |
LECOLincoln Electric Holdings, Inc. | $15.1B | $274.75 | $304.00 | +10.5% | Hold | 25.1x | 22 |
DHRDanaher Corporation | $126.1B | $178.23 | $230.89 | +30.3% | Buy | 21.0x | 43 |
RGENRepligen Corporation | $7.1B | $126.57 | $158.67 | +20.2% | Buy | 65.9x | 24 |
AZTAAzenta, Inc. | $1.0B | $22.27 | $44.50 | +90.9% | Buy | 52.0x | 12 |
IDXXIDEXX Laboratories, Inc. | $43.3B | $545.73 | $747.50 | +33.0% | Buy | 38.3x | 22 |
Quick answers to the most common questions about buying MASS stock.
The consensus price target for MASS is $N/A, close to the current price of $8.66 (N/A% implied move). Based on 5 analyst estimates, the stock appears fairly valued near current levels.
MASS has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
MASS's current price is $8.66 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for MASS, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
MASS is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MASS stock forecast based on 5 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
MASS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MASS analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.